Artivion (AORT) Projected to Post Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is projected to issue its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $116.4190 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

Artivion Price Performance

Shares of NYSE:AORT opened at $39.53 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25. The firm has a market cap of $1.87 billion, a PE ratio of -164.70 and a beta of 1.59. The firm’s fifty day moving average is $44.07 and its 200-day moving average is $42.72.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AORT shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $51.00 price target on shares of Artivion in a research report on Wednesday, December 17th. Citizens Jmp lifted their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Insider Activity at Artivion

In other news, SVP Jean F. Holloway sold 7,315 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total value of $331,369.50. Following the completion of the sale, the senior vice president directly owned 156,093 shares in the company, valued at $7,071,012.90. This trade represents a 4.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider John E. Davis sold 6,563 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $300,979.18. Following the transaction, the insider directly owned 198,842 shares in the company, valued at approximately $9,118,894.12. This trade represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 196,243 shares of company stock worth $8,889,334 over the last quarter. Company insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in shares of Artivion by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 998,327 shares of the company’s stock valued at $45,542,000 after buying an additional 66,709 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion in the 3rd quarter worth about $27,000. Hancock Whitney Corp bought a new position in Artivion in the 3rd quarter valued at about $212,000. Dark Forest Capital Management LP acquired a new position in Artivion during the 3rd quarter valued at about $1,623,000. Finally, Voloridge Investment Management LLC increased its holdings in Artivion by 442.9% during the 3rd quarter. Voloridge Investment Management LLC now owns 220,076 shares of the company’s stock worth $9,318,000 after purchasing an additional 179,541 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.